Intercept Pharmaceuticals Inc Revenue Growth Rates (ICPT), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Intercept Pharmaceuticals inc   (NASDAQ: ICPT)
 

ICPT's Revenue Growth by Quarter and Year

Intercept Pharmaceuticals Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ICPT Revenue (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
4th Quarter December -
3rd Quarter September 88.79
2nd Quarter June 83.72
1st Quarter March 67.96
FY 240.47

ICPTs Annual Revenue
Intercept Pharmaceuticals Inc 's Revenue in the fiscal year 2022 $ 285.71 millions
Intercept Pharmaceuticals Inc 's Revenue in the fiscal year 2021 $ 363.47 millions
Intercept Pharmaceuticals Inc 's Revenue in the fiscal year 2020 $ 312.69 millions
Intercept Pharmaceuticals Inc 's Revenue in the fiscal year 2019 $ 252.00 millions
Intercept Pharmaceuticals Inc 's Revenue in the fiscal year 2018 $ 179.80 millions




ICPT Revenue third quarter 2023 Y/Y Growth Comment
Intercept Pharmaceuticals inc reported Revenue increase of 14.43% year on year in the third quarter 2023, to $ 88.79 millions, this is lower than Intercept Pharmaceuticals Inc 's recent average Revenue surge of 245.36%.

Looking into third quarter 2023 results within Major Pharmaceutical Preparations industry 107 other companies have achieved higher Revenue growth. While Intercept Pharmaceuticals Inc ' s Revenue growth of 14.43% ranks overall at the positon no. 999 in the third quarter 2023.


ICPT Revenue ( Y/Y Growth %) 2023
 2022 2021 2020
4th Quarter December - -16.43 % 10.96 % 16.46 %
3rd Quarter September 14.43 % -16.42 % 16.74 % 28.36 %
2nd Quarter June 16.67 % -25.7 % 25.02 % 16.52 %
1st Quarter March -23.28 % 8.47 % 12.4 % 39.04 %
FY   - -13.29 % 16.24 % -

Financial Statements
Intercept Pharmaceuticals Inc 's third quarter 2023 Revenue $ 88.79 millions ICPT's Income Statement
Intercept Pharmaceuticals Inc 's third quarter 2022 Revenue $ 77.59 millions Quarterly ICPT's Income Statement


ICPT Revenue (Quarter on Quarter Growth %)

 2023
 2022 2021 2020
4th Quarter December - -0.48 % -0.46 % 4.72 %
3rd Quarter September 6.05 % 8.12 % -3.88 % 2.94 %
2nd Quarter June 23.19 % -18.99 % 18.27 % 6.33 %
1st Quarter March -11.99 % -4.13 % -1.93 % 1.61 %
FY (Year on Year)   - -13.29 % 16.24 % -


Back to ICPT Growth rate Comparisons >> Back to ICPT Growth rate Comparisons >>


Revenue third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #108
Healthcare Sector #248
Overall #999

Revenue Y/Y Growth Statistics
High Average Low
4629.89 % 245.36 % -100 %
(Mar 31 2017)   (Dec 31 2015)
Revenue third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #108
Healthcare Sector #248
Overall #999
Revenue Y/Y Growth Statistics
High Average Low
4629.89 % 245.36 % -100 %
(Mar 31 2017)   (Dec 31 2015)

Revenue by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Intercept Pharmaceuticals Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
1140.45 % 40.31 % -100 %
(Jun 30 2016)  


ICPT's III. Quarter Q/Q Revenue Comment
Intercept Pharmaceuticals inc achieved in the III. Quarter 2023 below company average Revenue increase of 6.05% quarter on quarter, to $ 88.79 millions.

Within Major Pharmaceutical Preparations industry 106 other companies have achieved higher Revenue quarter on quarter growth. While Intercept Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 1097.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #107
Healthcare Sector #231
Overall #1097
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #107
Healthcare Sector #231
Overall #1097
Revenue Q/Q Growth Statistics
High Average Low
1140.45 % 40.31 % -100 %
(Jun 30 2016)  


ICPT's III. Quarter Q/Q Revenue Comment
Intercept Pharmaceuticals inc achieved in the III. Quarter 2023 below company average Revenue increase of 6.05% quarter on quarter, to $ 88.79 millions.

Within Major Pharmaceutical Preparations industry 106 other companies have achieved higher Revenue quarter on quarter growth. While Intercept Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 1097.


Intercept Pharmaceuticals Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2023)		 12 Months Ending
(Jun 30 2023)		 12 Months Ending
(Mar 31 2023)		 12 Months Ending
(Dec 31 2022)		 12 Months Ending
(Sep 30 2022)
Cumulative Revenue 12 Months Ending $ 317.68 $ 306.48 $ 294.52 $ 315.15 $ 330.33
Y / Y Revenue Growth (TTM) -3.83 % -11.31 % -20.48 % -13.29 % -6.77 %
Year on Year Revenue Growth Overall Ranking # 2685 # 1166 # 105 # 929 # 648
Seqeuential Revenue Change (TTM) 3.65 % 4.06 % -6.54 % -4.6 % -4.41 %
Seq. Revenue Growth (TTM) Overall Ranking # 2560 # 2882 # 231 # 1708 # 668


Cumulative Revenue growth Comment
Intercept Pharmaceuticals Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Jun 30 2023. If the fiscal year would end in Sep 30 2023, Intercept Pharmaceuticals Inc 's annual Revenue decline would be -3.83% year on year to $318 millions.

In the Healthcare sector 420 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1166 to 2685.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 147
Healthcare Sector # 421
Overall # 2685

Revenue TTM Y/Y Growth Statistics
High Average Low
415.66 %
 43.56 %
-92.43 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 147
Sector # 407
S&P 500 # 2560
Cumulative Revenue growth Comment
Intercept Pharmaceuticals Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Jun 30 2023. If the fiscal year would end in Sep 30 2023, Intercept Pharmaceuticals Inc 's annual Revenue drop would be -3.83% year on year to $318 millions.

In the Healthcare sector 420 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1166 to 2685.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 147
Healthcare Sector # 421
Overall # 2685

Revenue TTM Y/Y Growth Statistics
High Average Low
415.66 %
43.56 %
-92.43 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 147
Sector # 407
S&P 500 # 2560




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
ICPT's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue drop for the quarter ending Sep 30 2023 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2023
Veru Inc 25.22%$ 25.223 millions
Rennova Health Inc 25.20%$ 25.201 millions
AnTix Holdings, Inc.25.15%$ 25.150 millions
Qhslab Inc 24.91%$ 24.908 millions
Treace Medical Concepts Inc 23.30%$ 23.304 millions
Lifemd Inc 23.25%$ 23.250 millions
Atara Biotherapeutics Inc 23.21%$ 23.211 millions
Iradimed Corporation23.10%$ 23.102 millions
Personalis Inc 22.81%$ 22.809 millions
Myriad Genetics Inc 22.70%$ 22.698 millions
Exact Sciences Corporation22.53%$ 22.530 millions
Ensign Group Inc22.18%$ 22.180 millions
Guardant Health Inc 21.83%$ 21.827 millions
Privia Health Group Inc 21.69%$ 21.692 millions
Corcept Therapeutics Inc21.50%$ 21.501 millions
Biodesix Inc 21.46%$ 21.464 millions
Lifestance Health Group Inc 20.84%$ 20.838 millions
Becton Dickinson And Company20.46%$ 20.459 millions
Apyx Medical Corp20.45%$ 20.452 millions
Deciphera Pharmaceuticals Inc 20.40%$ 20.401 millions
Airsculpt Technologies Inc 20.32%$ 20.315 millions
Zai Lab Limited20.31%$ 20.313 millions
Zynex inc 20.22%$ 20.219 millions
Alpine Immune Sciences Inc 20.03%$ 20.031 millions
Lemaitre Vascular Inc 19.95%$ 19.952 millions
Irhythm Holdings Inc 19.83%$ 19.831 millions
Bolt Biotherapeutics Inc 19.70%$ 19.697 millions
Mimedx Group Inc 19.55%$ 19.550 millions
Veracyte Inc 19.20%$ 19.203 millions
Sanuwave Health Inc 18.89%$ 18.891 millions


About Intercept Pharmaceuticals Inc Revenue Growth Rates (ICPT), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Intercept Pharmaceuticals Inc (CIK 1270073).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001558370-23-017790
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Intercept Pharmaceuticals Inc ’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.